摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

α-solanine | 20562-02-1

中文名称
——
中文别名
——
英文名称
α-solanine
英文别名
alpha solanine;solanine;alpha-Solanin;(2R,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-2-[[(1S,2S,7S,10R,11S,14S,15R,16S,17R,20S,23S)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracos-4-en-7-yl]oxy]-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
α-solanine化学式
CAS
20562-02-1
化学式
C45H73NO15
mdl
——
分子量
868.072
InChiKey
ZGVSETXHNHBTRK-OTYSSXIJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    285℃ (dec.)
  • 沸点:
    780.78°C (rough estimate)
  • 密度:
    1.40±0.1 g/cm3 (20 ºC 760 Torr)
  • 溶解度:
    甲醇(微溶,加热),吡啶(微溶,超声处理),水(微溶,加热)
  • LogP:
    5.670 (est)
  • 颜色/状态:
    SLENDER NEEDLES FROM 85% ALC
  • 旋光度:
    SPECIFIC OPTICAL ROTATION: -60 DEG @ 20 °C/D (PYRIDINE)
  • 解离常数:
    PK @ 15 °C= 6.66; K= 2.2X10-7

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    61
  • 可旋转键数:
    8
  • 环数:
    9.0
  • sp3杂化的碳原子比例:
    0.96
  • 拓扑面积:
    241
  • 氢给体数:
    9
  • 氢受体数:
    16

ADMET

毒理性
  • 副作用
神经毒素 - 其他中枢神经系统神经毒素
Neurotoxin - Other CNS neurotoxin
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
毒理性
  • 人类毒性摘录
低浓度的α-茄碱刺激了培养的人类成纤维细胞的生长,而较高浓度(大于30微克/毫升)则具有显著的抑制作用。放射自显影研究表明,细胞生长的刺激是由于G1期的缩短。用高剂量的α-茄碱处理的细胞的福尔根显微密度测量显示G2期细胞异常积累。由于α-茄碱对细胞生长的刺激或抑制作用,它可能作为人类致畸剂。
LOW CONCN OF ALPHA-SOLANINE STIMULATED THE GROWTH OF CULTURED HUMAN FIBROBLASTS, WHILE HIGHER CONCN (GREATER THAN 30 MUG/ML) HAD A MARKEDLY INHIBITORY EFFECT. AUTORADIOGRAPHIC STUDIES INDICATED THAT THE STIMULATION OF CELL GROWTH WAS DUE TO A SHORTENING OF THE G1 PHASE. FEULGEN MICRODENSITOMETRY OF CELLS TREATED WITH HIGH DOSES OF ALPHA-SOLANINE REVEALED AN ABNORMAL ACCUM OF CELLS IN G2. BY VIRTUE OF EITHER ITS STIMULATORY OR ITS INHIBITORY EFFECT ON CELL GROWTH, ALPHA-SOLANINE COULD ACT AS A HUMAN TERATOGEN.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 人类毒性摘录
发芽的马铃薯摄入已经描述为致命中毒,但是马铃薯中通常的浓度(小于0.01%)没有毒性意义。
FATAL POISONING HAS BEEN DESCRIBED FROM THE INGESTION OF SPROUTING POTATOES, BUT THE USUAL CONCN IN POTATOES (LESS THAN 0.01%) HAS NO TOXIC SIGNIFICANCE.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 非人类毒性摘录
/颠茄碱/...对消化道粘膜产生直接刺激作用,并且一旦被吸收进入血液,会引起红细胞的溶血。它还会产生中枢神经系统的兴奋随后是抑制,抑制呼吸和运动中枢,并且在大量摄入时,会导致心脏骤停。
/SOLANINE/...EXERTS A DIRECT IRRITANT EFFECT ON THE MUCOUS MEMBRANES OF THE ALIMENTARY TRACT AND, ON ABSORPTION INTO THE BLOOD STREAM, BRINGS ABOUT HEMOLYSIS OF THE RED CELLS. IT ALSO PRODUCES CENTRAL NERVOUS SYSTEM STIMULATION FOLLOWED BY DEPRESSION, DEPRESSION OF THE RESP AND MOTOR CENTERS AND, IN LARGE DOSES, CARDIAC ARREST.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 非人类毒性摘录
土豆摄入中毒的类型包括:1)神经型,主要表现为昏迷和抑郁症状;这通常与2)胃型一起出现,其特征是流涎、呕吐、腹泻和其它胃肠道刺激的迹象;以及3)发疹型,伴随溃疡性口炎、结膜炎、腹泻和腿部出现水泡和鳞片状湿疹。
...TYPES OF POISONING FROM INGESTION OF POTATOES: 1) A NERVOUS FORM IN WHICH SIGNS OF STUPOR AND DEPRESSION PREDOMINATE; THIS IS USUALLY SEEN TOGETHER WITH 2) THE GASTRIC TYPE, CHARACTERIZED BY SALIVATION, VOMITING, DIARRHEA AND OTHER SIGNS OF GI IRRITATION; AND 3) AN EXANTHEMATOUS FORM, ASSOC WITH ULCERATIVE STOMATITIS, CONJUNCTIVITIS, DIARRHEA AND A VESICULAR AND SCURFY ECZEMA OF THE LEGS.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    Xn
  • 安全说明:
    S1,S24/25,S25,S45
  • 危险类别码:
    R22
  • WGK Germany:
    3
  • 海关编码:
    29399990
  • 危险品运输编号:
    UN 1544
  • 包装等级:
    III
  • 危险类别:
    6.1(b)
  • 储存条件:
    充氩密封在0°C以下的温度下,并保持干燥和避光保存。

SDS

SDS:de5896ba3c5b0b9e723a4999158ad49a
查看

制备方法与用途

生物活性方面,α-茄碱是马铃薯中的一种重要甾体类生物碱,具有抑制癌细胞生长并诱导其凋亡的能力。

反应信息

  • 作为反应物:
    描述:
    solasonineα-solanine盐酸 作用下, 以 乙醇 为溶剂, 反应 3.5h, 生成 (22R,25R)-spirosol-5-en-3β-ol; hydrochloride
    参考文献:
    名称:
    Further syntheses of cyproterone acetate
    摘要:
    本发明涉及从索拉索丁合成环丙孕酮醋酸酯(17α-乙酰氧基-6-氯-1α,2α-亚甲基-4,6-孕二烯-3,20-二酮)的改进方法。本发明的方法比先前技术更短,因此更经济。
    公开号:
    EP1359154A1
点击查看最新优质反应信息

文献信息

  • Method for the separation of triglycoalkaloids
    申请人:SOLBEC PHARMACEUTICALS LTD.
    公开号:US20040030109A1
    公开(公告)日:2004-02-12
    In accordance with the present invention there is provided a method for the separation of a triglycoalkaloid in which the triglycoside portion comprises &agr;-L-rhamnopyranosyl-(1→2gal)-O-&bgr;-D-glucopyranosyl-(1→3gal)-&bgr;-D-galactopyranose (or 6-deoxy-&agr;-L-mannopyranosyl-(1→2)-O-[&bgr;-D-glucopyranosyl-(1→3)]-&bgr;-D-galactopyranoside) (‘an rhamnose-glucose-galactose triglycoalkaloid’) from a triglycoalkaloid in which the triglycoside portion is &agr;-L-rhamnopyranosyl-(1→2glu)-O-&agr;-L-rhamnopyranosyl-(1→4glu)-&bgr;-D-glucopyranose (‘a rhamnose-rhamnose-glucose triglycoalkaloid’) in a mixture containing both, the method comprising the steps of: Combining the mixture with a portion of alcoholic solvent; Causing or allowing a substantial portion of the rhamnose-rhamnose-glucose triglycoalkaloid to dissolve, thereby generating an alcoholic solution substantially of the rhamnose-rhamnose-glucose triglycoalkaloid, and a solid substantially comprising the rhamnose-glucose-galactose triglycoalkaloid; and Separating the solid substantially comprising the rhamnose-glucose-galactose triglycoalkaloid from the solution substantially of the rhamnose-rhamnose-glucose triglycoalkaloid.
    根据本发明提供了一种用于分离三糖生物碱的方法,其中三糖苷部分包括α-L-鼠李糖苷-(1→2半乳糖)-O-β-D-葡萄糖苷-(1→3半乳糖)-β-D-半乳糖(或6-去氧-α-L-甘露糖苷-(1→2)-O-[β-D-葡萄糖苷-(1→3)]-β-D-半乳糖苷)(称为“鼠李糖-葡萄糖-半乳糖三糖生物碱”),从其中三糖苷部分为α-L-鼠李糖苷-(1→2葡)-O-α-L-鼠李糖苷-(1→4葡)-β-D-葡萄糖苷(称为“鼠李糖-鼠李糖-葡萄糖三糖生物碱”)的混合物中分离出来,该方法包括以下步骤:将混合物与部分醇溶剂混合;导致或允许大部分鼠李糖-鼠李糖-葡萄糖三糖生物碱溶解,从而生成基本上由鼠李糖-鼠李糖-葡萄糖三糖生物碱组成的醇溶液,以及基本上由鼠李糖-葡萄糖-半乳糖三糖生物碱组成的固体;分离基本上由鼠李糖-葡萄糖-半乳糖三糖生物碱组成的固体与基本上由鼠李糖-鼠李糖-葡萄糖三糖生物碱组成的溶液。
  • [EN] METHOD FOR THE SEPARATION OF TRIGLYCOALKALOIDS<br/>[FR] PROCEDE DE SEPARATION DE TRIGLYCOALCALOÏDES
    申请人:SOLBEC PHARMACEUTICALS LTD
    公开号:WO2004002998A1
    公开(公告)日:2004-01-08
    In accordance with the present invention there is provided a method for the separation of a triglycoalkaloid in which the triglycoside portion comprises α-L-rhamnopyranosyl-(1→2gal)-O-β-D-glucopyranosyl-(1→3gal)-ß-D-galactopyranose (or 6-deoxy-a-L-mannopyranosyl-(1→2)-O-[ß-D-glucopyranosyl-(1→3)]-ß-D-galactopyranoside) ('an rhamnose-glucose-galactose triglycoalkaloid') from a triglycoalkaloid in which the triglycoside portion is a-L-rhamnopyranosyl-(1→2glu)-O-a-L-rhamnopyranosyl-(1→4glu)-ß-D-glucopyranose ('a rhamnose-rhamnose-glucose triglycoalkaloid') in a mixture containing both, the method comprising the steps of: Combining the mixture with a portion of alcoholic solvent; Causing or allowing a substantial portion of the rhamnose-rhamnose-glucose triglycoalkaloid to dissolve, thereby generating an alcoholic solution substantially of the rhamnose-rhamnose-glucose triglycoalkaloid , and a solid substantially comprising the rhamnose-glucose-galactose triglycoalkaloid; and Separating the solid substantially comprising the rhamnose-glucose-galactose triglycoalkaloid from the solution substantially of the rhamnose-rhamnose-glucose triglycoalkaloid.
    根据本发明提供了一种用于从含有α-L-鼠李糖苷-(1→2半乳糖)-O-β-D-葡萄糖苷-(1→3半乳糖)-ß-D-半乳糖苷(或6-去氧-α-L-甘露糖苷-(1→2)-O-[ß-D-葡萄糖苷-(1→3)]-ß-D-半乳糖苷)('一种鼠李糖-葡萄糖-半乳糖三糖生物碱')中分离三糖生物碱的方法,其中三糖苷部分是α-L-鼠李糖苷-(1→2葡)-O-α-L-鼠李糖苷-(1→4葡)-ß-D-葡萄糖苷('一种鼠李糖-鼠李糖-葡萄糖三糖生物碱')的混合物,该方法包括以下步骤:将混合物与部分酒精溶剂结合;导致或允许大部分鼠李糖-鼠李糖-葡萄糖三糖生物碱溶解,从而生成基本上由鼠李糖-鼠李糖-葡萄糖三糖生物碱的酒精溶液,以及基本上由鼠李糖-葡萄糖-半乳糖三糖生物碱组成的固体;并将基本上由鼠李糖-葡萄糖-半乳糖三糖生物碱组成的固体与基本上由鼠李糖-鼠李糖-葡萄糖三糖生物碱的溶液分离。
  • [EN] PIPERIDINIC DERIVATIVES, PHARMACEUTIC COMPOSITIONS CONTAINING THE SAME AND PREPARATION PROCESSES<br/>[FR] DERIVES DE PIPERIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES POUR LES PREPARER
    申请人:UNIV RIO DE JANEIRO
    公开号:WO2006039767A1
    公开(公告)日:2006-04-20
    The present invention provides pharmaceutical compositions containing new molecules capable of inhibiting acetylcholinesterase, thus being useful in the treatment of pathologies associated to cholinergic transmission, such as memory related disorders, neurodegenerative disorders such as Alzheimer's Disease, Miastenia Gravis or in the treatment of intoxications induced by chemical agents of central action; the production processes of those compositions are also described here.
    本发明提供了一种药物组合物,其中包含能够抑制乙酰胆碱酯酶的新分子,因此对于治疗与胆碱能传递相关的病理状况非常有用,例如与记忆有关的疾病,神经退行性疾病如阿尔茨海默病,重症肌无力或由中枢作用的化学物质引起的中毒;本发明还描述了这些组合物的生产过程。
  • PLANT WITH ALTERED CONTENT OF STEROIDAL GLYCOALKALOIDS
    申请人:YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    公开号:US20160122775A1
    公开(公告)日:2016-05-05
    The present invention relates to genetically modified plants by key genes involved in the biosynthesis of steroidal alkaloids. These plants have altered content of steroidal (glyco)alkaloids. Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids are provided.
    本发明涉及通过参与类固醇生物合成的关键基因进行基因改造的植物。这些植物具有改变的类固醇(糖)生物碱含量。提供了含有降低抗营养类固醇糖生物碱含量的茄科作物植物。
  • Native potato protein isolates
    申请人:Coöperatie Avebe U.A.
    公开号:EP1920662A1
    公开(公告)日:2008-05-14
    The invention relates to a process for native potato protein isolation, to native potato protein isolates, to the use thereof, and to a food product comprising a native potato protein isolate. The invention provides a novel isolation process for obtaining highly pure native potato protein isolates having a glycoalkaloid concentration of less than 150 ppm.
    本发明涉及一种马铃薯原生蛋白分离工艺、马铃薯原生蛋白分离物、其用途以及含有马铃薯原生蛋白分离物的食品。 本发明提供了一种新颖的分离工艺,用于获得高纯度的原生马铃薯蛋白分离物,其糖醛酸浓度低于 150 ppm。
查看更多